|
KR20080032562A
|
|
Retroviral vectors with improved safety
|
|
KR20060106989A
|
|
Human interleukin-11 mutants having improved biological activity
|
|
KR20050099147A
|
|
Composition for gene therapy of a cancer comprising a nucleic acid encoding human interferon-alpha1
|
|
US7279568B2
|
|
Highly efficient eukaryotic expression vector comprising an exogenous transcription regulatory element
|
|
US6838280B2
|
|
Construction of high efficiency retroviral vector for gene therapy of hunter syndrome
|
|
KR20030075718A
|
|
Hybrid hepatocyte growth factor gene which has a high expression efficiency and expresses two heterotypes of hepatocyte growth factor
|
|
CN1455682A
|
|
Compositions for gene therapy of rheumatoid arthritis including gene encoding anti-angiogenic protein or parts thereof
|
|
KR20020085940A
|
|
Oligonucleotide primers specific for retrovirus and a method for the quantitation of retroviral titer using same
|
|
KR20010069245A
|
|
High efficiency retroviral vector which contains genetically engineered cellular non-coding sequence harboring splice acceptor
|
|
KR20000006334A
|
|
High efficiency retroviral vectors that contain none of viral coding sequences
|
|
KR20000046969A
|
|
Eukaryotic cell expressing vector containing a expression regulating factor derived from the heterologous genes with the strong transcription activity
|
|
KR100336490B1
|
|
Immunotoxin to hiv infected cells, containing conjugate of cell toxicity protein and antibody to env protein of hiv
|
